Literature DB >> 34784562

Predictors of outcomes following liver transplant in hepatopulmonary syndrome: An OPTN database analysis.

Arun Jose1, Shimul A Shah2, Nadeem Anwar3, Courtney R Jones4, Francis X McCormack5, Kenneth E Sherman3, Jean M Elwing5.   

Abstract

Hepatopulmonary syndrome (HPS) is a type of pulmonary vascular disease occurring exclusively in those with underlying liver disease, associated with significant mortality in patients awaiting liver transplantation (LT). LT is curative in HPS, and these patients are granted Model for End Stage Liver Disease (MELD) exception points to expedite LT. The purpose of this study is to use multivariable competing risk Accelerated Failure Time models and propensity matching to examine the relationship between pre-LT hypoxemia and post-LT outcomes in HPS. We performed a retrospective cohort study of UNOS/OPTN database of all adult patients undergoing LT between January 1, 2006 and January 12, 2020. Pre-LT PaO2 was significantly associated with post-LT mortality in HPS, with each 1 mmHg increase in PaO2 significantly decreasing the risk of post-LT mortality (coefficient 0.039, HR = 0.95, p = 0.001). HPS patients with a pre-LT PaO2 < 54 mmHg demonstrated increased mortality following LT as compared to matched non-HPS cirrhotic patients. We conclude that HPS patients with a PaO2, 54 mmHg are at increased risk of post-LT mortality and may identify high-risk patients who would benefit from additional resources during LT, and that the effects of HPS MELD exception points to optimize post-LT outcomes should be continuously re-evaluated.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  End-stage liver disease; Hepatopulmonary syndrome; Survival rate; Transplant

Mesh:

Substances:

Year:  2021        PMID: 34784562      PMCID: PMC8671258          DOI: 10.1016/j.rmed.2021.106683

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  30 in total

1.  The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis.

Authors:  L J Wei
Journal:  Stat Med       Date:  1992 Oct-Nov       Impact factor: 2.373

2.  Hepatitis C in a New Era: A Review of Current Therapies.

Authors:  Troy Kish; Andrew Aziz; Monica Sorio
Journal:  P T       Date:  2017-05

3.  Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience.

Authors:  Sarah Raevens; Xavier Rogiers; Anja Geerts; Xavier Verhelst; Undine Samuel; Marieke van Rosmalen; Gabriela Berlakovich; Jean Delwaide; Olivier Detry; Frank Lehner; Jens Mittler; Silvio Nadalin; Frederik Nevens; Jacques Pirenne; Fuat Saner; Stefan Schneeberger; Dirk Stippel; Jerovšek Marjana Turk; Mathe Zoltan; Roberto Ivan Troisi; Hans Van Vlierberghe; Isabelle Colle
Journal:  Eur Respir J       Date:  2019-01-31       Impact factor: 16.671

4.  Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview.

Authors:  Mateo Porres-Aguilar; Jose T Altamirano; Aldo Torre-Delgadillo; Michael R Charlton; Andres Duarte-Rojo
Journal:  Eur Respir Rev       Date:  2012-09-01

5.  International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension.

Authors:  Michael J Krowka; Michael B Fallon; Steven M Kawut; Valentin Fuhrmann; Julie K Heimbach; Michael A E Ramsay; Olivier Sitbon; Ronald J Sokol
Journal:  Transplantation       Date:  2016-07       Impact factor: 4.939

Review 6.  Hepatopulmonary Syndrome and Portopulmonary Hypertension: The Pulmonary Vascular Enigmas of Liver Disease.

Authors:  Michael J Krowka
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-03-02

7.  Hepatopulmonary syndrome: favorable outcomes in the MELD exception era.

Authors:  Vivek N Iyer; Karen L Swanson; Rodrigo Cartin-Ceba; Ross A Dierkhising; Charles B Rosen; Julie K Heimbach; Russell H Wiesner; Michael J Krowka
Journal:  Hepatology       Date:  2013-02-15       Impact factor: 17.425

8.  Prevalence and severity of hepatopulmonary syndrome and its influence on survival in cirrhotic patients evaluated for liver transplantation.

Authors:  J M Pascasio; I Grilo; F J López-Pardo; F Ortega-Ruiz; J L Tirado; J M Sousa; M J Rodriguez-Puras; M T Ferrer; M Sayago; M A Gómez-Bravo; A Grilo
Journal:  Am J Transplant       Date:  2014-04-14       Impact factor: 8.086

9.  Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates.

Authors:  Michael B Fallon; Michael J Krowka; Robert S Brown; James F Trotter; Steven Zacks; Kari E Roberts; Vijay H Shah; Neil Kaplowitz; Lisa Forman; Keith Wille; Steven M Kawut
Journal:  Gastroenterology       Date:  2008-06-20       Impact factor: 22.682

10.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.

Authors:  Peter C Austin
Journal:  Pharm Stat       Date:  2011 Mar-Apr       Impact factor: 1.894

View more
  1 in total

1.  Unmasking Hypoxia in Cirrhosis Patients: Six-Minute Walk Test as a Screening Tool for Hepatopulmonary Syndrome.

Authors:  Abhishek Singhai; Manaswinee Mallik; Pragya Jain
Journal:  Adv Biomed Res       Date:  2022-06-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.